These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38639400)

  • 21. Cysteine metabolic engineering and selective disulfide reduction produce superior antibody-drug-conjugates.
    Procopio-Melino R; Kotch FW; Prashad AS; Gomes JM; Wang W; Arve B; Dawdy A; Chen L; Sperry J; Hosselet C; He T; Kriz R; Lin L; Marquette K; Tchistiakova L; Somers W; Rouse JC; Zhong X
    Sci Rep; 2022 May; 12(1):7262. PubMed ID: 35508689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion.
    Dimasi N; Fleming R; Zhong H; Bezabeh B; Kinneer K; Christie RJ; Fazenbaker C; Wu H; Gao C
    Mol Pharm; 2017 May; 14(5):1501-1516. PubMed ID: 28245132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Properties of Cysteine-Conjugated Antibody-Drug Conjugates Are Impacted by the IgG Subclass.
    Datta-Mannan A; Choi H; Stokell D; Tang J; Murphy A; Wrobleski A; Feng Y
    AAPS J; 2018 Sep; 20(6):103. PubMed ID: 30255287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates.
    Acchione M; Kwon H; Jochheim CM; Atkins WM
    MAbs; 2012; 4(3):362-72. PubMed ID: 22531451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics.
    Thompson P; Fleming R; Bezabeh B; Huang F; Mao S; Chen C; Harper J; Zhong H; Gao X; Yu XQ; Hinrichs MJ; Reed M; Kamal A; Strout P; Cho S; Woods R; Hollingsworth RE; Dixit R; Wu H; Gao C; Dimasi N
    J Control Release; 2016 Aug; 236():100-16. PubMed ID: 27327768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability.
    Sussman D; Westendorf L; Meyer DW; Leiske CI; Anderson M; Okeley NM; Alley SC; Lyon R; Sanderson RJ; Carter PJ; Benjamin DR
    Protein Eng Des Sel; 2018 Feb; 31(2):47-54. PubMed ID: 29370435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Site-specific antibody-drug conjugate heterogeneity characterization and heterogeneity root cause analysis.
    Cao M; De Mel N; Jiao Y; Howard J; Parthemore C; Korman S; Thompson C; Wendeler M; Liu D
    MAbs; 2019; 11(6):1064-1076. PubMed ID: 31198090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conjugation site analysis of antibody-drug-conjugates (ADCs) by signature ion fingerprinting and normalized area quantitation approach using nano-liquid chromatography coupled to high resolution mass spectrometry.
    Sang H; Lu G; Liu Y; Hu Q; Xing W; Cui D; Zhou F; Zhang J; Hao H; Wang G; Ye H
    Anal Chim Acta; 2017 Feb; 955():67-78. PubMed ID: 28088282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Universal Affinity Capture Liquid Chromatography-Mass Spectrometry Assay for Evaluation of Biotransformation of Site-Specific Antibody Drug Conjugates in Preclinical Studies.
    Kotapati S; Passmore D; Yamazoe S; Sanku RKK; Cong Q; Poudel YB; Chowdari NS; Gangwar S; Rao C; Rangan VS; Cardarelli PM; Deshpande S; Strop P; Dollinger G; Rajpal A
    Anal Chem; 2020 Jan; 92(2):2065-2073. PubMed ID: 31860282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug deconjugation-assisted peptide mapping by LC-MS/MS to identify conjugation sites and quantify site occupancy for antibody-drug conjugates.
    Wang T; Huang ZA; Zhou M; Wang R; Li Y; Guo L; Cao X; Huang J
    J Pharm Biomed Anal; 2024 Jun; 243():116098. PubMed ID: 38493753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. One-Pot Assembly of Dual-Site-Specific Antibody-Drug Conjugates via Glycan Remodeling and Affinity-Directed Traceless Conjugation.
    Tang C; Zeng Y; Zhang J; Zheng X; Tang F; Yao X; Jiang ZX; Shi W; Huang W
    Bioconjug Chem; 2023 Apr; ():. PubMed ID: 37022330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Site-specific antibody drug conjugates for cancer therapy.
    Panowski S; Bhakta S; Raab H; Polakis P; Junutula JR
    MAbs; 2014; 6(1):34-45. PubMed ID: 24423619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Agitation-Induced Aggregation of Lysine- And Interchain Cysteine-Linked Antibody-Drug Conjugates.
    Johann F; Wöll S; Winzer M; Gieseler H
    J Pharm Sci; 2024 May; 113(5):1265-1274. PubMed ID: 38070776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thiolation of Q295: Site-Specific Conjugation of Hydrophobic Payloads without the Need for Genetic Engineering.
    Benjamin SR; Jackson CP; Fang S; Carlson DP; Guo Z; Tumey LN
    Mol Pharm; 2019 Jun; 16(6):2795-2807. PubMed ID: 31067063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells.
    Poźniak M; Porębska N; Krzyścik MA; Sokołowska-Wędzina A; Jastrzębski K; Sochacka M; Szymczyk J; Zakrzewska M; Otlewski J; Opaliński Ł
    Mol Med; 2021 May; 27(1):46. PubMed ID: 33962559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. N-terminal selective conjugation method widens the therapeutic window of antibody-drug conjugates by improving tolerability and stability.
    Ko MJ; Song D; Kim J; Kim JY; Eom J; Sung B; Son YG; Kim YM; Lee SH; You WK; Jung J
    MAbs; 2021; 13(1):1914885. PubMed ID: 33904380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Site-Specific Chemical Conjugation of Antibodies by Using Affinity Peptide for the Development of Therapeutic Antibody Format.
    Kishimoto S; Nakashimada Y; Yokota R; Hatanaka T; Adachi M; Ito Y
    Bioconjug Chem; 2019 Mar; 30(3):698-702. PubMed ID: 30606013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Highly Potent, Anthracycline-based Antibody-Drug Conjugates Generated by Enzymatic, Site-specific Conjugation.
    Stefan N; Gébleux R; Waldmeier L; Hell T; Escher M; Wolter FI; Grawunder U; Beerli RR
    Mol Cancer Ther; 2017 May; 16(5):879-892. PubMed ID: 28258164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and Validation of Linkers for Site-Specific Preparation of Antibody-Drug Conjugates Carrying Multiple Drug Copies Per Cysteine Conjugation Site.
    Kumar A; Mao S; Dimasi N; Gao C
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
    Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
    PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.